Cumberland Pharmaceuticals (NASDAQ:CPIX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIXGet Rating) in a research note published on Tuesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Performance

Cumberland Pharmaceuticals stock opened at $2.30 on Tuesday. Cumberland Pharmaceuticals has a 52 week low of $1.89 and a 52 week high of $7.51. The company has a current ratio of 1.94, a quick ratio of 1.52 and a debt-to-equity ratio of 0.46. The stock has a market cap of $33.72 million, a P/E ratio of -4.89 and a beta of 0.28. The stock has a 50 day moving average of $2.38 and a 200-day moving average of $2.29.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of CPIX. M Holdings Securities Inc. bought a new stake in Cumberland Pharmaceuticals in the first quarter valued at about $30,000. Acadian Asset Management LLC grew its position in shares of Cumberland Pharmaceuticals by 27.8% in the 1st quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock worth $529,000 after acquiring an additional 40,949 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Cumberland Pharmaceuticals by 6.3% in the 1st quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock valued at $1,818,000 after acquiring an additional 38,100 shares during the last quarter. Institutional investors own 18.48% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

(Get Rating)

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Read More

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.